Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus

We characterized the population pharmacokinetics of anifrolumab, a type I interferon receptor–blocking antibody. Pharmacokinetic data were analyzed from the anifrolumab (intravenous [IV], every 4 weeks) arms from 5 clinical trials in patients with systemic lupus erythematosus (SLE) (n = 664) and hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Almquist, Joachim, Kuruvilla, Denison, Mai, Tu, Tummala, Raj, White, Wendy I., Tang, Weifeng, Roskos, Lorin, Chia, Yen Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540432/
https://www.ncbi.nlm.nih.gov/pubmed/35383948
http://dx.doi.org/10.1002/jcph.2055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540432/
https://www.ncbi.nlm.nih.gov/pubmed/35383948
http://dx.doi.org/10.1002/jcph.2055

Ejemplares similares